Santhera seeks EMA approval for idebenone in Duchenne muscular dystrophy

This article was originally published here

The Swiss pharma company is looking for a conditional marketing authorization (CMA) for idebenone for DMD patients who are not using glucocorticoids for the treatment of their respiratory

The post Santhera seeks EMA approval for idebenone in Duchenne muscular dystrophy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply